Your Bank Wasn't Built For Your Business. Vellis Is.
Biotech companies face banking friction, payment restrictions and financial infrastructure challenges that generic providers aren't equipped to handle. Vellis provides payment processing and business banking directly — built for complex regulatory environments, high-value transactions and cross-border research and commercial operations.
No intermediaries. You work directly with Vellis.
A sector at the frontier of science and commerce — and one that mainstream financial infrastructure consistently fails to serve properly.
Global biotech market value
Yet most banks still apply generic commercial risk frameworks to biotech businesses without understanding their regulatory or scientific profile.
Annual growth rate of the global biotech sector
Your banking infrastructure needs to scale with one of the fastest-growing sectors in the world.
Projected global biotech market value by 2030A sector this strategically important deserves better than generic banking.
The Real Problem
Biotech companies operate at the intersection of scientific research, regulatory compliance and commercial activity — a space that mainstream banks and payment providers have never been fully equipped to serve. Here's what that costs you.
Your bank or payment processor flags your account because of your sector classification.
Biotech companies are routinely flagged by mainstream financial providers who can't assess the specific nature of their operations. Research compounds, biological materials, clinical revenue, grant income and commercial product sales all create transaction patterns that automated risk systems weren't designed to handle. Your account is reviewed, payments are delayed, and you're left managing your bank instead of your business.
Complex revenue models create billing and payment infrastructure challenges.
Biotech revenue streams are rarely straightforward — grant funding, licensing fees, milestone payments, research service contracts, product commercialisation revenue. Standard billing infrastructure wasn't built for this complexity. Managing diverse revenue streams with generic tools creates reconciliation overhead and operational fragility.
Cross-border research and commercial operations require international banking infrastructure.
Biotech companies regularly operate across multiple jurisdictions — research facilities in one country, commercial operations in another, investors in a third. Each cross-border relationship requires banking and payment infrastructure that can handle the complexity without creating friction at every transaction. Without the right setup, international biotech operations accumulate banking overhead that has nothing to do with the science.
High-value transactions and unusual payment patterns trigger unnecessary reviews.
Milestone payments, licensing agreements and large research contracts are standard in biotech — but look unusual to generic banking risk systems. The result: delays on critical payments, compliance reviews that slow commercial momentum, and a banking relationship that treats legitimate scientific commerce as a risk to be managed.
What Vellis Provides
Direct payment processing and business banking — built and operated by Vellis for the regulatory complexity, diverse revenue models and international operations of biotech businesses.
Payment processing
Stable, sector-aware processing
Accept payments for commercial products, research services and licensing fees without account flags driven by sector classification.
High-value transaction support
Process milestone payments, licensing fees and large research contracts without processing limits or settlement delays.
Multi-currency processing
Manage international commercial and research revenue with live market rates and no hidden margins.
Recurring billing for research service contracts
Manage ongoing research agreements and service contracts without manual invoicing.
Chargeback & fraud monitoring
Calibrated to biotech transaction profiles, not a generic retail risk model.
Business banking
Accounts built for biotech revenue models
Diverse, complex revenue streams assessed by people who understand the biotech commercial environment.
Multi-entity structuring
For biotech groups operating across research entities, commercial subsidiaries and international operations.
Fast onboarding
No months-long compliance reviews that treat your regulated business like an unknown risk.
EMI & fintech-backed accounts
Access to Vellis-operated solutions beyond what traditional banks offer to biotech businesses.
Dedicated sector expertise
Supported by people who understand biotech operations, not a generic helpdesk.
Pain Point to Outcome
What changes when your financial infrastructure actually fits your business.
Your current pain point
Account flagged due to sector classification
Complex revenue streams creating billing friction
High-value milestone payments delayed by reviews
International operations creating banking overhead
FX costs on cross-border research and commercial revenue
Generic banking treating biotech transactions as anomalies
What you get with Vellis
Infrastructure built for biotech operations — fewer flags, faster resolution.
Payment infrastructure that handles diverse biotech revenue models.
High-value transaction support without unnecessary compliance friction.
Multi-jurisdiction banking from a single point of contact.
Multi-currency processing with live rates and no hidden margins.
Risk assessment by people who understand your commercial and research operations.
Why Vellis
Built for regulated, complex and internationally operating businesses — with the track record to prove it.
Companies operating directly on Vellis infrastructure.
Industries served, from regulated to high-risk.
Global
Coverage across multiple jurisdictions and currencies.
You work directly with Vellis - no intermediaries, no black boxes. From your first consultation to your live account, every step is handled by Vellis. You always know who owns your setup, who to call, and what happens next.
We operate research and commercial entities across four countries. Vellis built our banking structure around our actual operations — handling everything from licensing revenue to international research contracts without the usual compliance friction.
CFO, Biotech Company
Who We Work With
Vellis directly serves biotech businesses across their growth and commercialisation journey.
Biotech startups
Establishing professional banking and payment infrastructure from the first commercial activity.
Clinical-stage biotech companies
Managing research service revenue, grant income and pre-commercial transactions.
Commercial-stage biotech businesses
Processing licensing fees, milestone payments and product commercialisation revenue.
Contract research organisations (CROs)
Managing research service contracts and international client payments.
How It Works
From first conversation to live infrastructure — handled directly by Vellis, start to finish.
Tell us about your business
Share your company structure, revenue model, jurisdictions and banking requirements. Not a generic form — a real conversation with a Vellis specialist who understands the commercial and regulatory environment biotech businesses operate in.
We build the right setup for you
Vellis designs a payment and banking configuration tailored to your revenue streams, entity structure and jurisdictions. An early-stage research business and a multi-entity commercial biotech group have fundamentally different needs — your setup reflects that.
Go live on Vellis infrastructure
Onboarding is guided by Vellis end-to-end. Once live, you operate directly on our infrastructure — with a dedicated point of contact, full visibility over your setup, and no middlemen in the chain.
Stop letting banking infrastructure slow your biotech business down.
The global biotech sector is growing at nearly 14% a year. Your financial infrastructure should keep pace with your science — not create friction at every commercial milestone. 500+ businesses already operate directly on Vellis.
FAQ
Biotech Businesses
Vellis is a direct provider — not a broker, not a referral service. We provide payment processing and business banking directly to your business. No intermediaries, no black boxes. You always know who owns your setup, who to contact, and how your payments and accounts are structured.
Yes. From a pre-revenue research business to a fully commercialised biotech group, the solution we build is always tailored to your actual revenue model, entity structure and growth stage.
Yes. Vellis operates globally, across any country that is not OFAC listed. We support biotech businesses with research, development and commercial operations across multiple jurisdictions.
Yes. We work with the full range of biotech business models — from contract research organisations managing service revenue to commercial-stage businesses processing licensing and product sale revenue.
Mainstream providers can't assess biotech operations properly — they apply generic commercial risk logic to a sector that requires specialist understanding. Vellis processes payments through infrastructure built for biotech businesses. Your revenue profile is understood from the start. The only case where it would be difficult for us to help is if your business has been placed on a MATCH list.
Yes. Vellis infrastructure supports high-value transactions — milestone payments, licensing fees and large research contracts are accounted for in your setup, not flagged as anomalies.
Yes. Vellis supports multi-currency processing so you can manage revenue across your international operations with live market rates and no hidden conversion margins.
If a payment dispute arises, you have a direct point of contact at Vellis — not a generic support queue. We review the situation with you and help manage the process on your behalf.
Unfortunately, yes. Traditional banks apply generic risk criteria that weren't designed for biotech revenue models. Unusual transaction patterns — milestone payments, grant income, research service contracts — can all trigger reviews with no bearing on actual risk. Vellis accounts are managed by people who understand biotech businesses — your revenue profile is expected and understood.
Yes. Multi-entity and multi-jurisdiction banking is core to what Vellis does. As long as the country is not OFAC listed, Vellis structures your accounts across jurisdictions from a single point of contact.
A standard account is built for a generic business profile. A Vellis account is structured around yours — your revenue streams, entity structure, jurisdictions and commercial stage. In practice: fewer unnecessary reviews, faster resolution when questions arise, and direct access to Vellis rather than a generic business banking system.
A real conversation — not a sales pitch. Format and timing are flexible: call, video or email, based on your preference. A Vellis specialist will ask about your company structure, revenue model, research and commercial activities, current payment and banking setup, and international operations. From there, you get a clear picture of what we'd recommend and what the process looks like. No pressure, no jargon, no commitment required.
For most businesses, the process is done within a couple of weeks. After your consultation, we give you a clear timeline based on your specific structure and jurisdiction — with no surprises mid-application.
Standard business documentation, plus any regulatory authorisations, research licences or commercial certifications relevant to your activities and jurisdictions. Vellis gives you a complete, tailored document list upfront so there are no unexpected requests mid-process.